CytoMed Therapeutics Limited Ordinary Shares - Asset Resilience Ratio
CytoMed Therapeutics Limited Ordinary Shares (GDTC) has an Asset Resilience Ratio of 2.39% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how CytoMed Therapeutics Limited Ordinary Shares's Asset Resilience Ratio has changed over time. Check GDTC capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down CytoMed Therapeutics Limited Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GDTC stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $200.35K | 2.39% |
| Total Liquid Assets | $200.35K | 2.39% |
Asset Resilience Insights
- Limited Liquidity: CytoMed Therapeutics Limited Ordinary Shares maintains only 2.39% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CytoMed Therapeutics Limited Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare CytoMed Therapeutics Limited Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for CytoMed Therapeutics Limited Ordinary Shares (2019–2024)
The table below shows the annual Asset Resilience Ratio data for CytoMed Therapeutics Limited Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.99% | $200.35K | $10.07 Million | +1.61pp |
| 2023-12-31 | 0.38% | $47.19K | $12.40 Million | +0.16pp |
| 2022-12-31 | 0.22% | $11.56K | $5.25 Million | -0.03pp |
| 2021-12-31 | 0.25% | $15.27K | $6.10 Million | -0.89pp |
| 2020-12-31 | 1.14% | $43.59K | $3.82 Million | -1.74pp |
| 2019-12-31 | 2.88% | $84.80K | $2.94 Million | -- |
About CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I… Read more